NCT07611552Not yet recruiting
Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss
The Effect of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Medications for Weight Loss: a Randomized Double-blind Controlled Trial
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
The goal of this double-blind randomized placebo-controlled supplement study is to investigate if the supplement of inulin (prebiotics, 10 grams per day) has beneficial effects on cardiometabolic risk factors in overweight or obese individuals receiving glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications for weight loss.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 21 May 2026
- Start date
- Jun 2026
- Primary completion date
- Nov 2026
- Lead sponsor
- Huazhong University of Science and Technology
- Diseases
- Obesity
- NCT number
- NCT07611552
What you commit to
- Study type: Interventional
- Planned participants: 600
- From Jun 2026 to the primary completion date, Nov 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months;
Other illness
- Be allergic or intolerance to inulin-type substances;
Other
- Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt);
- Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials;
- Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding;
- Deemed unsuitable for participation by the investigator's judgment.
Who the study is looking for
- Be overweight or obese (meeting any of the following criteria):
- Obesity: BMI \>=28 kg/m²;
- Overweight (BMI \>= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease.
- Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months.
- Age 18-64 years.
- Consent to participate and sign the informed consent form.
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture Coordinator of this site? Confirm its status | Enshi | China | Unknown status |
| Sinopharm Dongfeng General Hospital Coordinator of this site? Confirm its status | Shiyan | China | Unknown status |
| Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
| Xiangyang No.1 People's Hospital Coordinator of this site? Confirm its status | Xiangyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.